Lupin Share Price (LUPIN)
Check the latest share price of Lupin, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 11 Jul 2025
NSE
Lupin Stock Performance
Get live Lupin share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,875Day's Price Range₹1,903.852 Week's Low
52 Week's High
₹1,766.0552-Week Price Range₹2,402.9
| Returns % | |
| 1 Month Return | -6.5 % |
| 3 Month Return | -3.78 % |
| 1 Year Return | + 4.26 % |
| 3 Year Return | + 194.89 % |
| 5 Year Return | + 117.84 % |
| Market Stats | |
| Previous Close | ₹1,894.80 |
| Open | ₹1,895.00 |
| Volume | 15.11L |
| Upper Circuit | ₹2,084.20 |
| Lower Circuit | ₹1,705.40 |
Lupin Fundamentals & Key Indicators
Check Lupin market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹86,538.57 Cr
Return on Equity (ROE)
11.92
PE Ratio (TTM)
26.33
Return on capital employed (ROCE)
13.96
Industry PE ratio
51.93
Beta (LTM)
0.79
P/B Ratio
3.58
Dividend Yield
0.49
PEG Ratio
0.88
Quarterly Earnings Growth YOY
112.48
EPS (TTM)
42.47
Sector
Pharmaceuticals
Book Value
313.59
Technical Analysis
Bearish
View Technical Analysis
How to invest in Lupin?
Investing in Lupin is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Lupin or LUPIN on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Lupin or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Lupin with just a few clicks!
Lupin Stock's Interest Amongst Investors
Lupin Valuation
Track how Lupin P/E has moved over time to understand its valuation trends.
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (26.33x)
July 10, 2025
Industry (51.93x)
July 10, 2025
Highest (517.33x)
December 2, 2022
Today’s Price to Earnings Ratio: 26.33x
Lupin Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Lupin.
based on 36 analysts
58.33%
Buy
30.56%
Hold
11.11%
Sell
58.33% of analysts recommend a 'BUY' rating for Lupin. Average target price of ₹2259.97
Source: S&P Global Market Intelligence
Lupin Share Price Target
Get share price movements and forecasts by analysts on Lupin.
Lupin price forecast by 36 analysts
Upside of19.27%
High
₹2626
Target
₹2259.97
Low
₹1889
Lupin target price ₹2259.97, a slight upside of 19.27% compared to current price of ₹1894.7. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:33.86%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:111.97%
Forecast
Actual
Source: S&P Global Market Intelligence
Lupin Financial Results
Get the annual and quarterly financial summary of Lupin, including revenue, profit, loss and more.
Indices Featuring Lupin Stock
Check stock indices that include Lupin.
Lupin Earnings and Dividends
View detailed summary of the earnings and dividend history of Lupin.
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 114.93% since last year same period to ₹772.52Cr in the Q4 2024-2025. On a quarterly growth basis, Lupin Ltd has generated -9.66% fall in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8.00 - translating a dividend yield of 0.63%.
Read More about Dividends
Lupin Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Lupin.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.92% | 0.00 | |
| Foreign Institutions | 21.46% | 0.00 | |
| Mutual Funds | 17.55% | 0.00 | |
| Retail Investors | 6.2% | 0.00 | |
| Others | 7.87% | 0.00 |
Lupin vs Peers
Compare market cap, revenue, PE, and other key metrics of Lupin with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 86,538.57 | 23.57% | 0.51 | 1,935 | 20,010 | |
| BUY | 13,812.24 | -4.25% | 0.52 | 413 | 2,013 | |
| BUY | 66,205.20 | 7.92% | 0.56 | 3,168 | 29,001 | |
| HOLD | 97,901.54 | 34.34% | 0.64 | 3,854 | 19,547 | |
| BUY | 73,429.38 | 24.61% | 0.53 | NA | NA |
Lupin News & Key Events
Latest news and events in one place to help you make informed investing decisions in Lupin.
Lupin Partners with Zentiva for Biosimilar Expansion - 09 Jul, 2025
Lupin has entered a strategic licensing and supply agreement with Zentiva for its biosimilar Certolizumab Pegol, enhancing global market reach and sharing profits. The deal includes an upfront payment of $10 million and potential milestone payments of up to $50 million.Lupin Launches Ipratropium Bromide Nasal Spray in US - 04 Jul, 2025
Lupin has launched Ipratropium Bromide nasal spray in the US, a generic version of Atrovent, aiming to increase complex generics revenue share to 62% by FY30.Lupin Launches Subsidiary for Consumer Healthcare - 03 Jul, 2025
Lupin Ltd has launched a wholly owned subsidiary focused on consumer healthcare, aiming to enhance its presence in India's growing self-care and OTC healthcare markets.Lupin Announces Strategic Moves and FDA Approval - 01 Jul, 2025
Lupin has carved out its consumer healthcare business into a subsidiary, LupinLife Consumer Healthcare, effective July 1, 2025. The stock rose 1.56% following this announcement. Additionally, Lupin received FDA approval for Loteprednol Etabonate Ophthalmic Gel, securing 180 days of exclusivity.Lupin Transfers OTC Business to Subsidiary - 30 Jun, 2025
Lupin has executed a Business Transfer Agreement to transfer its Over-the-Counter Consumer Healthcare Business to its wholly owned subsidiary, LUPINLIFE Consumer Healthcare, effective July 1, 2025.Lupin Prepares US Strategy for Etanercept Patent Expiry - 29 Jun, 2025
Lupin Ltd is strategizing for the US commercialization of its autoimmune biologic Etanercept, aiming to finalize plans before the drug's patent expires in 2029.Lupin Secures USFDA Approval for Constipation Drug - 25 Jun, 2025
Lupin Ltd has received USFDA approval for its Prucalopride Tablets, indicated for chronic idiopathic constipation. The product, manufactured in Goa, has an estimated market potential of $184 million annually.Lupin Partners for Tiotropium Inhaler in China - 16 Jun, 2025
Lupin has entered a license and supply agreement with Sino Universal Pharmaceuticals to commercialize Tiotropium Dry Powder Inhaler in China, aiming to address the growing demand for respiratory treatments. This partnership reflects Lupin's commitment to expanding its presence in the Chinese pharmaceutical market and enhancing its global respiratory health portfolio.US Court Ruling Impacts Lupin's Generic Myrbetriq Sales - 13 Jun, 2025
A US District Court's rejection of generic firms' arguments regarding the Astellas patent is a setback for Lupin and Zydus, affecting their Myrbetriq sales potential.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.92% to 17.55% in Mar 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 49.4% return, outperforming this stock by 45.1%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 5.82K Cr → 5.72K Cr (in ₹), with an average decrease of 1.7% per quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 46.95% to 46.92% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.26% to 6.20% in Mar 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 855.16 Cr → 772.52 Cr (in ₹), with an average decrease of 9.7% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 22.04% to 21.46% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, LUPIN stock has moved down by -4.4%
About Lupin
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Revenue: ₹5,562.20Cr as on March 2025 (Q4 FY25)
Net Profit: ₹782.38Cr as on March 2025 (Q4 FY25)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin Ltd |
| Industry | Pharmaceuticals |
| CEO | M D Gupta |
| E-voting on shares | Click here to vote |
Mutual Funds that own Lupin
Check out the Mutual Funds with significant holdings in Lupin.
FAQs
What is Lupin share price today?
Lupin share price today stands at ₹1894.7, Open: ₹1895, Previous Close: ₹1894.8, High: ₹1903.8, Low: ₹1875, 52 Week High: ₹2402.9, 52 Week Low: ₹1766.05.
What is today's traded volume of Lupin?
Today's traded volume of Lupin is 15.11L. Which means that 15.11L shares of Lupin were bought and sold on the stock market during today's trading session.
What is Lupin's market cap today?
Today's market capitalisation of Lupin is ₹86,538.57 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Lupin?
Lupin’s 52 week high is ₹2402.9 and 52 week low is ₹1766.05. The current share price of Lupin is ₹1894.7, which is -21.15% down from its 52 week high and 7.28% up from its 52 week low.